UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~ 14September 10, 2025

BioScience Health Innovations, Inc.

(Exact name of ~~the~~ registrant as specified in its charter)

Nevada	333-234487	98-1498782
(State or other jurisdiction of	(Commission	(IRS Employer
(State of Incorporation)	(Commission File Number)	(IRS Employer ID No.)
of incorporation)	File Number)	Identification No.)

2722 S West Temple
Salt Lake City, UT 84115

(Address of ~~principal~~Principal ~~executive~~Executive ~~offices~~Offices) ~~(Zip code)~~

~~Registrant’s telephone number, including area code:~~ (801) 949-0791

(Registrant's Telephone Number including Area Code)

NOWTRANSIT INC.

(Former name or ~~former~~ address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the ~~Registrant~~registrant under any of the following provisions ~~(see General Instruction A.2 below)~~:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class Trading symbol(s) Name of exchange on which registered N/A N/A N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒. ☒

SECTION 5. CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.03 Amendments to Articles of Incorporation or Bylaws

On September ~~February 21~~10, 2025, ~~Nowtransit~~BioScience Health Innovations, Inc. (the “Company”) amended its Restated Certificate of Incorporation~~, as amended~~ (the “Certificate of Incorporation”), to effect a ~~change~~reverse split of the Company’s ~~name~~common ~~from~~stock ~~“Nowtransit,~~on ~~Inc.”~~the tobasis ~~“BioScience~~that ~~Health~~4 ~~Innovations, Inc.”~~ (~~the~~four) such ~~“Name~~shares ~~Change”~~of common stock shall become 1 (one) share of common stock. The ~~Name~~Reverse ~~Change~~Split became effective on ~~February~~September 2110, 2025.

The Board of Directors of the Company (the “Board”) approved the ~~Name~~Reverse ~~Change~~Split pursuant to ~~NVS~~ Section 78.~~380~~390 of the ~~General Corporation Law of the State of~~ Nevada Revised Statutes. The ~~Name~~ ~~Change~~Reverse Split does not affect the rights of the Company’s stockholders, and there were no other changes to the Certificate of Incorporation. A copy of the certificate of amendment to the Restated Certificate of Incorporation filed with the Secretary of State of the State of Nevada to affect the ~~Name~~Reverse ~~Change~~Split is filed as Exhibit 3.1 and incorporated herein by reference.

~~In connection with the Name Change, the Board~~Item ~~also~~5.07 ~~approved~~Submission ~~an amendment and restatement~~ of ~~the~~Matters ~~Company’s Amended and Restated Bylaws solely~~ to ~~reflect~~a ~~the~~Vote ~~Name Change (as amended and restated, the “Amended and Restated Bylaws”) effective as~~ of ~~February~~Security ~~21, 2025~~Holders. ~~A copy of the Amended and Restated Bylaws is filed as Exhibit 3.2 and incorporated herein by reference.~~

~~(d)~~The Reverse ~~Exhibits~~Split of the Company’s Common shares was approved by the written consent of a majority of the shares of the Company entitled to vote on the Reverse Split.

		Incorporated by Reference			Filed or Furnished
Exhibit Number	Exhibit Description	Form	Date	Number	Herewith
3.1	Certificate of Amendment of Amended and Restated Certificate of Incorporation
3.2	Amended and Restated Bylaws of BioScience Health Innovations, Inc
104	Cover Page Interactive Data File (formatted as Inline XBRL)

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.		Description
3.1		Certificate of Amendment to the Amended and Restated Certificate of Incorporation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~as amended,~~ the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto ~~duly~~ duly authorized.

	BioScience Health Innovations, Inc
	BioScience Health Innovations, Inc.
March 14, 2025	By:	/s/ Darren Lopez
	a Nevada corporation
		Darren Lopez,
Date: October 16, 2025	By:	/s/ Darren Lopez
		Chief Executive Officer
	Name:	Darren Lopez
	Title:	Chief Executive Officer

Filing Compare · BioScience Health Innovations, Inc.